Welcome to our dedicated page for Galmed Pharmaceu news (Ticker: GLMD), a resource for investors and traders seeking the latest updates and insights on Galmed Pharmaceu stock.
Galmed Pharmaceuticals Ltd. (GLMD) is a clinical-stage biopharmaceutical company advancing innovative therapies for liver, metabolic, and fibro-inflammatory diseases. This news hub provides investors and industry professionals with timely updates on the company's lead compound Aramchol, a novel SCD1 inhibitor being evaluated in late-stage clinical trials for non-alcoholic steatohepatitis (NASH).
Access official press releases and curated analysis covering clinical developments, regulatory milestones, and strategic partnerships. Our repository includes updates on Aramchol's unique mechanism of action targeting hepatic fat metabolism, patent filings for combination therapies, and progress in addressing complex liver pathologies.
Key content categories include clinical trial results, FDA communications, financial reporting disclosures, and scientific conference presentations. Bookmark this page for centralized access to Galmed's evolving research initiatives and business developments in the competitive NASH therapeutics landscape.
Galmed Pharmaceuticals (NASDAQ: GLMD), a clinical-stage biopharmaceutical company specializing in liver, cardiometabolic diseases and GI oncological indications, has announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission.
The report is accessible on both the SEC website and Galmed's Investor Relations platform. Shareholders can request free copies of the annual report through the company's Investor Relations Department.
Galmed Pharmaceuticals (Nasdaq: GLMD) has published one-year results of the Open-Label part (ARCON) of its global Phase 3 trial of Aramchol in 150 patients with NASH and fibrosis (ARMOR) in Hepatology. The study demonstrated that Aramchol 300mg BID resulted in a high rate of subjects with histological fibrosis improvement. Aramchol, a down regulator of SCD-1, has shown potential as a potent anti-fibrotic compound for treating metabolic dysfunction associated steatohepatitis (MASH).
The study utilized three objective measurements: NASH CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis. The rigorous multimodality histology assessment, including FibroNest™ AI digital pathology, allowed researchers to identify regression changes and affirm the AI Digital Pathology analysis findings.
Galmed Pharmaceuticals (Nasdaq: GLMD) announced plans to expand its drug development activities beyond liver diseases to include cancer and major cardiometabolic diseases. This decision is based on recent results from the Open-Label part of its Phase 3 NASH study, new scientific publications on SCD1's role, and an extended cash runway. The company plans to:
1. Develop Aramchol-based drug combinations for advanced colorectal and hepatic cancers.
2. Create novel Aramchol-based combinations targeting cardiac fibrosis.
3. Release new data from in-vitro and ex-vivo studies in Q4 2024.
Galmed raised $7.5 million through warrant exercises and equity line drawdowns. The expansion leverages Aramchol, the most clinically advanced SCD1 oral inhibitor, which has shown an excellent safety profile with metabolic and anti-fibrotic effects in Phase 2 and 3 trials.
FAQ
What is the current stock price of Galmed Pharmaceu (GLMD)?
What is the market cap of Galmed Pharmaceu (GLMD)?
